Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Major trial tests cutting radiation for kids with hodgkin lymphoma

NCT ID NCT02684708

Cure Sponsor: University of Giessen Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This large phase 3 trial enrolled over 2900 children and teens with classical Hodgkin lymphoma. The goal was to see if doctors could reduce the use of radiation therapy without lowering cure rates. Some patients also received stronger chemotherapy to make up for less radiation. The study aimed to find a balance that keeps survival high while reducing long-term harm from treatment.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
chemotherapy (cyclophosphamide, vincristine, prednisone, dacarbazine, etoposide, doxorubicin)
What this could lead to
If successful, this could show that many children with Hodgkin lymphoma can be cured with less radiation, reducing long-term side effects.
What could go wrong
This trial is complete, but results may not apply to all patients. Reducing radiation might increase relapse risk in some groups.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 3

Large-scale testing in a bigger group. Usually the last step before a treatment can be approved.

Participants

2,921 people

The number who actually took part.

Started

Oct 2015

Finished

Oct 2025

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

Up to 25 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * histologically confirmed primary diagnosis of classical Hodgkin's lymphoma * patients under 18 years of age on the date of written informed consent. In specialized Teenage and Young Adult (TYA) units in France, Italy and UK patients up to under 25 years of age can also be enrolled. Lower age limits will be country specific according to national laws or formal insurance requirements that may preclude very young patients. * written informed consent of the patient and/or the patient's parents or guardian according to national laws * negative pregnancy test within 2 weeks prior to starting treatment for female patients with childbearing potential Exclusion Criteria: * prior chemotherapy or radiotherapy for other malignancies * pre-treatment of Hodgkin's lymphoma (except for 7-10 days steroid pre-phase of a large mediastinal tumour) * diagnosis of lymphocyte-predominant Hodgkin's lymphoma * other (simultaneous) malignancies * contraindication or known hypersensitivity to study drugs * severe concomitant diseases (e.g. immune deficiency syndrome) * known HIV-positivity * residence outside the participating countries where long term follow-up cannot be guaranteed * pregnancy and/or lactation * patients who are sexually active and are unwilling to use adequate contraception during therapy and for one month after last trial treatment * current or recent (within 30 days prior to date of written informed consent) treatment with another investigational drug or participation in another interventional clinical trial

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Classical Hodgkin lymphoma are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

classic Hodgkin lymphoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Classical Hodgkin lymphoma

Contacts and locations

Locations

  • CHUV - Centre Hospitalier Universitaire Vaudois = LS, Départment femme - meré - enfant, Service de pédiatrie, Unité d'hématologie-oncologie pédiatrique

    Lausanne, 1011, Switzerland

  • Clinic of Pediatric Oncology University Children's Hospital

    Bratislava, 83340, Slovakia

  • Department of Medical Oncology Oslo University Hospital

    Oslo, 0424, Norway

  • Department of Pediatric Hematology/Oncology (5054) The Child and Youth Clinic, University Hospital of Copenhagen

    Copenhagen, 2100, Denmark

  • Dpt. of Pediatric Hematology and Oncology, Faculty Hospital Motol

    Prague, 15006, Czechia

  • Head of Department of Pediatric Oncology and Hematology, Polish-American Pediatric Institute, Jagiellonian University Medical Faculty

    Krakow, 30-663, Poland

  • Justus Liebig University of Giessen

    Giessen, 35392, Germany

  • Our Lady's Children's Hospital, Crumlin

    Dublin, 12, Ireland

  • Paediatric haemato-oncology, University Hospitals of Leuven

    Leuven, 3000, Belgium

  • Pediatric Hematology & Oncology Children´s University Hospital

    Uppsala, 75185, Sweden

  • Pediatric Radiotherapy and Youth Area Unit C.R.O. - Centro di Riferimento Oncologico IRCCS

    Aviano, 33081, Italy

  • Princess Máxima Center for pediatric oncology

    Utrecht, 3508, Netherlands

  • Royal Children's Hospital and Monash Medical Centre Royal Children's Hospital

    Victoria Park, 3052, Australia

  • Sección de Onco-Hematología Pediátrica Hospital Universitario Virgen Macarena y Virgen del Rocío

    Seville, 41071, Spain

  • Service d'Oncohématologie, Hopital d'Ènfants Armand Trousseau

    Paris, 75571, France

  • St. Anna Kinderspital

    Vienna, 1090, Austria

  • Starship Blood and Cancer Centre, Starship Children's Hospital

    Auckland, 1142, New Zealand

  • Tel Aviv University Schneider Children's Medical Center of Israel The Rina Zaizov Pediatric Hematology Oncology Division

    Petah Tikva, 49202, Israel

  • University College London Hospitals

    London, NW1 2PG, United Kingdom

More trials for these conditions

Other studies related to the condition(s) this trial covers.